Issue link: http://clhia.uberflip.com/i/406567
34 • Start a dialogue on creating a common, national minimum drug formulary to provide greater consistency in the system; and • Governments work with all stakeholders towards the development of a collaborative, end- to-end approach to the approval and funding of orphan drugs in order to ensure Canadians' access to new orphan drugs going forward. These reforms may take time to implement and the industry is cognisant of the pressing cost and equity challenges with the current system. While more fundamental reform is being pursued, therefore, the industry believes that a number of high priority, shorter term and tactical reforms should be undertaken to: • Automatically list generic drugs on provincial formularies once they have been approved as bio-equivalent as a means to quickly realize significant costs savings for all Canadians; • Implement improved processes for the transition of patients between public and private coverage in order to address the complexity and uncertainty that exists with the current system; and • Develop a monitoring framework for off-label prescribing in order to address patient safety and cost escalation concerns. The Canadian life and health insurers believe that the time for reform is now. We are committed to meaningful reform in this sector and look forward to engaging with governments and other stakeholders to ensure Canadians continue to benefit from a strong pharmacare system into the future.